TY - JOUR
T1 - Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens
AU - Deslouches, Berthony
AU - Steckbeck, Jonathan D.
AU - Craigo, Jodi K.
AU - Doi, Yohei
AU - Burns, Jane L.
AU - Montelaro, Ronald C.
N1 - Publisher Copyright:
© 2015 American Society for Microbiology.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.
AB - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=84921894902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921894902&partnerID=8YFLogxK
U2 - 10.1128/AAC.03937-14
DO - 10.1128/AAC.03937-14
M3 - Article
C2 - 25421473
AN - SCOPUS:84921894902
SN - 0066-4804
VL - 59
SP - 1329
EP - 1333
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 2
ER -
